StockNews.com began coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a research note issued to investors on Sunday. The firm issued a hold rating on the biotechnology company’s stock.
Calithera Biosciences Stock Performance
Shares of NASDAQ:CALA opened at $0.05 on Friday. The stock has a fifty day simple moving average of $0.02 and a two-hundred day simple moving average of $0.03. Calithera Biosciences has a 12-month low of $0.01 and a 12-month high of $0.50.
Institutional Trading of Calithera Biosciences
A number of hedge funds have recently bought and sold shares of CALA. Vanguard Group Inc. increased its position in Calithera Biosciences by 23.4% in the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company’s stock worth $415,000 after buying an additional 26,800 shares in the last quarter. Renaissance Technologies LLC increased its position in Calithera Biosciences by 13.8% in the third quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company’s stock worth $337,000 after buying an additional 13,855 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in Calithera Biosciences in the first quarter worth about $404,000. Goldman Sachs Group Inc. increased its position in Calithera Biosciences by 143.2% in the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock worth $50,000 after buying an additional 72,865 shares in the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in Calithera Biosciences in the first quarter worth about $404,000.
About Calithera Biosciences
Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.
See Also
- Five stocks we like better than Calithera Biosciences
- Canadian Penny Stocks: Can They Make You Rich?
- Silicon Motion Proves That AI in Motion Stays in Motion
- What is the Dogs of the Dow Strategy? Overview and Examples
- Undervalued UnitedHealth Group Won’t Be For Long
- How to Invest in Insurance Companies: A Guide
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
